Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$2.26
+5.6%
$3.43
$2.10
$381.10
$1.72M5.64124,760 shs43,778 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs230,443 shs
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$1.50
+1.4%
$1.57
$0.97
$19.44
$8.34M1.1463,409 shs89,460 shs
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
$0.36
+1.4%
$0.36
$0.29
$2.42
$8.22M1.36149,162 shs283,774 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.00%-15.67%-24.67%-66.76%-99.98%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%-75.00%-75.00%-75.00%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.00%+2.74%-1.32%+7.91%+149,999,900.00%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
0.00%+1.37%-3.56%+6.26%-84.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
1.8529 of 5 stars
3.53.00.00.00.00.01.3
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.3437 of 5 stars
0.05.00.00.00.00.80.0
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
2.0446 of 5 stars
2.83.00.00.00.52.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.00
Buy$219,040.009,691,935.40% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.00
N/AN/AN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
1.50
Reduce$0.4526.76% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.11M0.55N/AN/A$65.21 per share0.03
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$230K36.26N/AN/A($8.66) per share-0.17
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
$19.31M0.43N/AN/A$1.36 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/14/2025 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$166.52M-$32.81N/AN/AN/A-15,245.81%N/A-193.21%8/21/2025 (Estimated)
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$70.84M-$2.73N/AN/AN/AN/A-148.90%-112.17%8/13/2025 (Estimated)

Latest APVO, TRAW, TSBX, and OBSV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025N/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$83.20N/AN/AN/AN/AN/A
8/8/2025Q2 2025
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$0.16-$0.24-$0.08-$0.24N/AN/A
5/15/2025Q1 2025
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$84.20-$87.80-$3.60-$4.39N/AN/A
5/15/2025Q1 2025
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/AN/AN/AN/AN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
0.67
0.67
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/A
1.81
1.81
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
N/A
3.70
3.70

Institutional Ownership

CompanyInstitutional Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
8.06%
ObsEva SA stock logo
OBSV
ObsEva
17.52%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
7.95%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
52.51%

Insider Ownership

CompanyInsider Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.12%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
13.60%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
32.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
50760,000755,000Not Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
175.56 million4.81 millionOptionable
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
8223.14 million15.71 millionNot Optionable

Recent News About These Companies

Turnstone Biologics Corp. (TSBX) - Yahoo Finance
Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year
Turnstone Biologics to explore strategic alternatives
Turnstone Biologics downgraded to Neutral from Overweight at Piper Sandler

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$2.26 +0.12 (+5.61%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$2.25 -0.01 (-0.44%)
As of 08:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Traws Pharma stock logo

Traws Pharma NASDAQ:TRAW

$1.50 +0.02 (+1.35%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.52 +0.02 (+1.67%)
As of 08:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Turnstone Biologics stock logo

Turnstone Biologics NASDAQ:TSBX

$0.36 +0.01 (+1.43%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$0.35 0.00 (-0.28%)
As of 08/8/2025 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.